Efficacy and safety of antiplatelet therapy in COVID-19: Insights from a  meta-analysis of randomized controlled trials

CONCLUSION: Antiplatelet therapy does not confer mortality benefit in COVID-19 patients but lowers major thrombotic events while increasing major bleeding risks. Ongoing large RCTs will provide more information on the therapeutic value of this therapy.PMID:38469705 | DOI:10.5414/CP204497
Source: International Journal of Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Authors: Source Type: research